Galena Biopharma Inc (GALE) reported quarterly earnings results on Tuesday, May-10-2016. The company reported $-0.07 EPS for the quarter. Analysts had a consensus estimate of $-0.07. During the same quarter in the previous year, the company posted $-0.08 EPS.
Galena Biopharma Inc opened for trading at $1.22 and hit $1.26 on the upside on Friday, eventually ending the session at $1.25, with a gain of 2.46% or 0.03 points. The heightened volatility saw the trading volume jump to 6,02,990 shares. Company has a market cap of $227 M.
Galena Biopharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets including immunotherapy program led by its lead product NeuVax (nelipepimut-S) which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.